title: [Retinochoroidopathy after intravitreal anti-VEGF treatment].
abstract: A 74-year-old man presented with persistent metamorphopsias of the right eye 2 weeks after intravitreal injection of bevacizumab to treat choroidal neovascularization due to exudative age-related macular degeneration. The diagnosis reached was retinochoroiditis as an occult manifestation of sarcoidosis, possibly resulting from an intravitreal injection of bevacizumab. The patient received a prescription for 100 mg Ultralan to be taken daily for 3 days and then tapered in 3 day steps. During the further course no deterioration of the condition was observed.
authors.affiliation: Augenklinik der Technischen Universität München, Deutschland. m.maier@irz.tum.de
authors.forename: M
authors.initials: M
authors.lastname: Maier
authors.forename: N
authors.initials: N
authors.lastname: Feucht
authors.forename: I
authors.initials: I
authors.lastname: Lanzl
authors.forename: P
authors.initials: P
authors.lastname: Kook
authors.forename: C P
authors.initials: CP
authors.lastname: Lohmann
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002825:Chorioretinitis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*; D005448:Fluocortolone / Q000627:therapeutic use*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D005448:Fluocortolone